{"disease":{"id":"clostridium-difficile","name":"clostridium difficile"},"drugs":{"marketed":[{"drug_id":"fidaxomicin","indication_name":"Clostridium difficile infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dificid","generic_name":"FIDAXOMICIN","company_name":"Cubist Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide Antibacterial [EPC]","quality_score":65,"revenue":"410.0","mechanism":"Dificid works by inhibiting protein synthesis in bacteria, preventing them from reproducing and causing infection."},{"drug_id":"vancomycin","indication_name":"Clostridium difficile diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vancocin","generic_name":"vancomycin","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"bezlotoxumab","indication_name":"Clostridium difficile infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinplava","generic_name":"BEZLOTOXUMAB","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Zinplava works by binding to and neutralizing toxins produced by Clostridium difficile bacteria."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04014608","title":"Protocol for Admission Toxigenic C. Difficile Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":148549,"lead_sponsor_name":"Endeavor Health","has_results":false},{"nct_id":"NCT03349268","title":"Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection","phase":"NA","overall_status":"COMPLETED","enrollment_count":25732,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT03090191","title":"Clostridium Difficile Vaccine Efficacy Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":17535,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01887912","title":"Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":9302,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT03848689","title":"FQ Restriction for the Prevention of CDI","phase":"","overall_status":"COMPLETED","enrollment_count":5871,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT03223415","title":"Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":4138,"lead_sponsor_name":"Yves Longtin","has_results":false},{"nct_id":"NCT07261826","title":"Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Chen QiYi","has_results":false},{"nct_id":"NCT03857464","title":"C Difficile Near-patient Diagnostics","phase":"NA","overall_status":"COMPLETED","enrollment_count":3816,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT03503474","title":"COMBACTE-CDI Understanding the Burden of C. Difficile Infection","phase":"","overall_status":"COMPLETED","enrollment_count":3240,"lead_sponsor_name":"University of Leeds","has_results":true},{"nct_id":"NCT02968758","title":"Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains","phase":"NA","overall_status":"COMPLETED","enrollment_count":2461,"lead_sponsor_name":"Meridian Bioscience, Inc.","has_results":true},{"nct_id":"NCT03918629","title":"Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1994,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01241552","title":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1452,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03579459","title":"Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1317,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02996487","title":"Screening to Prophylax Against Clostridium Difficile Infection -","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1294,"lead_sponsor_name":"Corewell Health East","has_results":true},{"nct_id":"NCT01513239","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1203,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02896244","title":"AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment","phase":"","overall_status":"COMPLETED","enrollment_count":1007,"lead_sponsor_name":"MJM Bonten","has_results":false},{"nct_id":"NCT04075422","title":"Bezlotoxumab - in \"Real Life\" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.","phase":"","overall_status":"COMPLETED","enrollment_count":869,"lead_sponsor_name":"Fundacion SEIMC-GESIDA","has_results":false},{"nct_id":"NCT05192148","title":"Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile","phase":"NA","overall_status":"UNKNOWN","enrollment_count":840,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT03931941","title":"Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":793,"lead_sponsor_name":"Rebiotix Inc.","has_results":true},{"nct_id":"NCT04036058","title":"Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA","phase":"NA","overall_status":"COMPLETED","enrollment_count":780,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT04801862","title":"Natural History of Clostridioides Difficile Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":750,"lead_sponsor_name":"Hospital Universitario de Valme","has_results":false},{"nct_id":"NCT01987895","title":"Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT01983683","title":"Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":631,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT01691248","title":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01598311","title":"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01597505","title":"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04187430","title":"Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies","phase":"","overall_status":"UNKNOWN","enrollment_count":513,"lead_sponsor_name":"Emilio Bouza","has_results":false},{"nct_id":"NCT04567134","title":"Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Hanyang University Seoul Hospital","has_results":false},{"nct_id":"NCT03562741","title":"Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Krunal Patel","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT02951481","title":"Antimicrobial Stewardship Program for Clostridium Difficile Infection.","phase":"","overall_status":"COMPLETED","enrollment_count":403,"lead_sponsor_name":"José María Aguado García, MD, PhD","has_results":true},{"nct_id":"NCT03589768","title":"Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02254967","title":"A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":364,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT02797288","title":"Immune Response to C.Difficile Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":360,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT03244644","title":"Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Rebiotix Inc.","has_results":true},{"nct_id":"NCT02667418","title":"Optimal Treatment for Recurrent Clostridium Difficile","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":308,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT06311006","title":"Safety Registry of a Fecal Microbiota Transplant Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":305,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02561195","title":"A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03368105","title":"Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Medical University of Silesia","has_results":false},{"nct_id":"NCT02214771","title":"Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients","phase":"","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"Astellas Pharma S.A.S.","has_results":false},{"nct_id":"NCT04138706","title":"Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT03710694","title":"Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)","phase":"NA","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Da Volterra","has_results":false},{"nct_id":"NCT04305769","title":"Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT04960306","title":"Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":238,"lead_sponsor_name":"University of Pecs","has_results":false},{"nct_id":"NCT03654872","title":"Clostridium Difficile Virulence Mechanism Study (CDVM Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":227,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04698148","title":"Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","has_results":false},{"nct_id":"NCT01085591","title":"Study of CB-183,315 in Participants With Clostridium Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02179658","title":"A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03110133","title":"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"Finch Research and Development LLC.","has_results":true},{"nct_id":"NCT05622721","title":"REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Pennsylvania","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}